ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
L-carnitine improves polycystic ovary syndrome by increasing CYP11A1, estrogen receptor, and decreasing XNIP and VEGF expression.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- FAAH as a Molecular Regulator of Endocannabinoid Signaling: Mechanistic Insights into Reproductive, Metabolic, and Inflammatory Dysfunctions in Polycystic Ovary Syndrome.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Polycystic ovary syndrome (PCOS) is a reproductive disorder associated with infertility and causes other complications in different parts of the body. Many studies have reported reduced L-carnitine (LC) levels in these patients. The aim of the present study was to investigate the therapeutic effect of LC in an animal model of PCOS induced by estradiol valerate (EV). In this study, 15 adult female Wistar rats were divided into three groups: control group, PCOS group receiving EV (4 mg/kg body weight), and PCOS group treated with LC administered orally by gavage (100 mg/kg daily for 17 days). At the end of the treatment period, after euthanizing the animals, serum levels of LH, FSH, testosterone, insulin and glucose were analyzed, and histological, immuno-histochemical (IHC), and molecular examinations of the ovaries were performed. The results showed that LC significantly increased the expression of CYP11A1(cytochrome p450 11A1) (related to steroidogenesis) and TXNIP (thioredoxin interacting protein) (related to oxidative stress) and increased serum levels of follicle-stimulating hormone (FSH), reduced testosterone, luteinizing hormone (LH), glucose, insulin, and homeostasis model assessment-insulin resistance. Improvement in histological and morphometric changes of ovarian follicles as well as IHC expression of estrogen receptor and VEGF was observed in the treatment group. It appears that LC supplementation, through reducing weight, improving sex hormone levels, and enhancing ovarian structure, may offer a promising approach for alleviating complications associated with PCOS and reducing other related disorders. This protocol may be considered a potential future therapeutic intervention for PCOS, though further clinical investigations are required.
Indexed as
Identifiers
41838133What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.